LIFEVANTAGE CORP Write off of Deferred Debt Issuance Cost
LIFEVANTAGE CORP (LFVN) reported Write off of Deferred Debt Issuance Cost of $0 for the 12-month period ending 2018-06-30, per its 10-K filed 2018-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2018-08-15
- LIFEVANTAGE CORP write off of deferred debt issuance cost for the quarter ending 2017-06-30 was $0.00.
- LIFEVANTAGE CORP write off of deferred debt issuance cost for the quarter ending 2016-06-30 was $0.00.
- LIFEVANTAGE CORP write off of deferred debt issuance cost for fiscal 2018 was $0.00.
- LIFEVANTAGE CORP write off of deferred debt issuance cost for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- LIFEVANTAGE CORP write off of deferred debt issuance cost for fiscal 2016 was $1.54M.
- LIFEVANTAGE CORP write off of deferred debt issuance cost for fiscal 2015 was $0.00.
| Period end | Write off of Deferred Debt Issuance Cost | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 9 month | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|---|---|---|
| 2018-06-30 | $0.00 10-K · filed 2018-08-15 | |||
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-15 | $0.00 10-K · filed 2018-08-15 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | |||
| 2016-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-15 | $1.54M 10-K · filed 2018-08-15 | ||
| 2016-03-31 | $1.54M 10-Q · filed 2017-05-10 | |||
| 2016-03-30 | $1.50M 10-K · filed 2017-09-07 | |||
| 2015-06-30 | $0.00 10-K · filed 2017-09-07 | |||
| 2014-06-30 | $0.00 10-K · filed 2016-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |